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Abstract
There is a growing recognition that current preclinical models
do not reﬂect the tumormicroenvironment in cellular, biological,
and biophysical content and this may have a profound effect on
drug efﬁcacy testing, especially in the era of molecular-targeted
agents. Here, we describe amethod to directly embed low-passage
patient tumor–derived tissue into basement membrane extract,
ensuring a low proportion of cell death to anoikis and growth
complementation by coculture with patient-derived cancer-asso-
ciatedﬁbroblasts (CAF). A range of solid tumors proved amenable
to growth and pharmacologic testing in this 3D assay. A study of
30 early-stage non–small cell lung cancer (NSCLC) specimens
revealed high levels of de novo resistance to a large range of
standard-of-care agents, while histone deacetylase (HDAC) inhi-
bitors and their combination with antineoplastic drugs displayed
high levels of efﬁcacy. Increased resistance was seen in the pres-
ence of patient-derived CAFs for many agents, highlighting the
utility of the assay for tumor microenvironment-educated drug
testing. Standard-of-care agents showed similar responses in the
3D ex vivo and patient-matched in vivomodels validating the 3D-
Tumor Growth Assay (3D-TGA) as a high-throughput screen for
close-to-patient tumors using signiﬁcantly reduced animal num-
bers. Mol Cancer Ther; 15(4); 753–63. 2016 AACR.
Introduction
Currently, >90%of antineoplastic therapeutic agents that enter
human clinical trials fail to become registered for clinical use (1),
indicating the disconnect between current preclinical tumor
models and disease reality (2–4). Cell lines, grown in 2D in vitro
culture and in vivo as subcutaneous tumors, are the most widely
used tumor paradigm in both academic and pharmaceutical
research. Whist readily available and easy to use, these models
have been shown to be poorly predictive of clinical efﬁcacy (5). By
deﬁnition such lines have been selected for their ability to survive
on 2D plastic surfaces and are known to drift in phenotype (6).
Xenografts of such lines typically form rapidly growing, undif-
ferentiated tumors, lacking the architecture and biological phe-
notype of the tumors that they are meant to represent. Drug
resistance gene signatures of cell lines from the NCI-60 tumor
panel in 2D or xenograft culture bare no relation to freshly
isolated human tumor, beingmore closely matched to each other
than the 6 tumor indications they represented (7).
Xenografts directly established fromhuman tumors have tissue
architecture and phenotype more closely resembling that of
pancreatic (8), NSCLC (9, 10), and colorectal (11) cancers.
Expansion of patient-derived tumors in vivo can provide material
at early passage for ex vivo assays, such as the clonogenic assay,
which show promising correlation between drug response ex vivo
and that seen in the patient (12) but is not amenable to high-
throughput screening. The inﬂuence of paracrine factors produced
by tumor-recruited stroma and immune inﬁltrate on disease
progression has been demonstrated (13, 14), but preclinical
models incorporating heterogeneous cell populations are only
just beginning to emerge (15).
Recently, there has been a move towards 3D in vitro cancer
models (16). Cells grown on 2D culture surfaces display
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abnormal cell–cell interactions (17), cell–matrix interactions (if
present; ref. 18) and are prone to spatial artifacts such as apical–
basal polarization of ﬁbroblasts (19) or inappropriate polarity
and differentiation of epithelial cells (20). The overwhelming
adhesion signaling from 2D culture can swamp growth factor
signalingpathways, giving rise tounrepresentative pharmacologic
responses to growth factor receptor inhibitors (21) or apopto-
sis-inducing agents (22), including chemotherapies (23).
Therefore, 3D culture systems with minimal cell–cell, cell–
matrix perturbations incorporating close-to-patient cells such
as those generated in patient-derived xenograft (PDX) lines are
required. Transition of cells between solid tumor xenografts
and in vitro models has historically been problematic: direct
transfer into traditional 2D tissue culture has a high attrition
rate or results in growth of a highly selected subpopulation of
cells so there is a need for models which avoid anoikis (24) and
capture tumor heterogeneity.
We sought to develop a 3D ex vivo assay that was consistently
capable of growing tumor cells with minimal loss from low-
passage PDX lines, such that they were rapidly amenable to
pharmacologic assay. We strove to align the biochemical and
biophysical properties of the assay to the patient tumor micro-
environment (TME). This was achieved by development of the
3-Dimensional Tumor Growth Assay (3D-TGA; refs. 25, 26),
which utilizes a low stiffness laminin-rich extracellular matrix
(ECM; ref. 27) to embed tumor cells and admixing with stromal
cells to provide the paracrine signaling present in the TME of
solid tumors (13, 14). We describe the establishment and
application of a novel preclinical model utilizing tumor-
derived ECM and incorporating patient-derived tumor-associ-
ated stromal cells which allows proﬁling of humanized close-
to-patient xenografts at early passage.
Materials and Methods
Specimens and establishment of PDXs
Fresh surgical material from tumor resections at Nottingham
University Hospitals NHS Trust, were collected with informed
patient consent and National Research Ethics Service (NRES)
approval (NRES REC 10/H0405/6). Samples were used in accor-
dance with NRES approval (NRES REC 08/H0403/37). Samples
of tumor tissue were dissected, formalin-ﬁxed and parafﬁn-
embedded (FFPE) for immunohistochemistry. A small amount
of ﬁnelyminced tumor tissue was enzymatically disaggregated (as
below for xenograft tissue) and plated into 6-well tissue culture
plates inDMEM, 10%FBS, 2mmol/L glucose (Sigma) to establish
ﬁbroblasts; ﬁbroblasts were banked at early passage and used in
the 3D assay at less than passage 5. The majority of the ﬁnely
minced tumor was mixed with bone marrow–derived mesenchy-
mal stem cells (MSC) (5  105/mouse) (ScienCell) and resus-
pended in ice-cold Matrigel (200 mL/mouse; BD Biosciences).
Animal procedures were carried out under UK Home Ofﬁce
Licence (PPL 40/3559) by qualiﬁed persons holding UK Home
Ofﬁce Personal Licences in accordance with the 3R's framework
for humane animal research. Tumor samples were grafted sub-
cutaneously into sex-matched MF-1 nude or NOD/SCID mice
(Harlan). Initial grafting is referred to as passage 0 (P0). Upon
growth, tumors were surgically removed under anesthesia,
minced, and passaged on into further donor mice (P1, with the
addition ofMSCs andMatrigel as above) or taken for banking and
3D-TGA assays.
Disaggregation of xenograft tumors
Finely minced tumor was disaggregated using type II collage-
nase (100 U/mL; Invitrogen) and dispase (2.4 U/mL; Invitrogen)
in HBSS (Sigma) at 37C under constant rotation. Cells were
removed at 1 to 2 hourly intervals until the tumor was completely
disaggregated. Cell number and viability were determined using
trypan blue exclusion and analyzed by ﬂow cytometry for expres-
sion of EpCam (Supplementary Fig. S1 and Supplementary
Methods).
The 3D-TGA
Cells were resuspended in ice-cold Cultrex basement
membrane extract (BME) (3 mg/mL; Trevigen) diluted in mod-
iﬁed RPMI-1640 (Life Technologies; phenol red free with 6
mmol/L D-glucose and pH6.8) and plated at 2.5  104 tumor
cells  8.33  103 patient-derived CAFs/MSCs (Sciencell; per
well (100 mL) into low-adherent, black-walled, clear-bottom,
96-well plates (BrandTech) prewarmed to 37C. CAFs derived
from patient LU6 were used in all assays for NSCLC specimens
and MSCs for all other tumor types. Drugs were serially diluted
in modiﬁed RPMI-1640 and 50 mL added in triplicate wells of
the TGA on day 3. For the 384-well plate 3D-TGAs, a quarter of
the 96-well plate cell number and volumes and six replicate
wells were used. Drugs used in combination were premixed and
serially diluted together before adding to the assay. Drug
exposure was for 96 hours before ﬁnal endpoint readings. The
AlamarBlue assay [Invitrogen; 10% (v/v), 37C for 1 hour] was
used to monitor cell growth daily, using a ﬂuorescent plate
Reader (Flex Station II, Molecular Devices). Drug sensitivity
was calculated as a percentage of matched untreated control
and IC50 curves were determined using GraphPad Prism 5
(GraphPad Software Inc., nonlinear curve ﬁt of Y ¼ 100/
(1þ10((LogIC50-X)HillSlope). Error bars represent one standard
deviation. Drugs in combination were at constant ratios to
make them amenable to synergy testing using the Chou–Tala-
lay method (28) and CalcuSyn Software (Biosoft).
Immunohistochemistry
Immunohistochemistry and hematoxylin and eosin (H&E)
staining were performed on 5-mm tissue sections of FFPE tissue
using standard techniques and the manufacturer's recommenda-
tions for the following primary antibodies: anti-human E-Cad-
herin (DAKOCloneNCH-38) and anti-humanVimentin (DAKO,
Clone V9).
In vivo efﬁcacy testing
Established PDXs from donor mice were surgically removed
under anesthesia and tissue minced to passage on into mice for
efﬁcacy evaluation (passage 4–10, with the addition of MSCs
and Matrigel as above). Procedures were carried out under UK
Home Ofﬁce Licence (PPL 70/7317). When tumors reached
150 to 200 mm3, 6 to 10 mice each were randomized to
treatment and control groups, and treatment was initiated as
follows: carboplatin/paclitaxel 50/5 mg/kg i.p. weekly, 100
mg/kg pemetrexed i.p. weekly, erlotinib (25 or 50 mg/kg p.o.
q.d.) or matched vehicle control. Tumor size was measured
using calipers (length and width) three times weekly, and
tumor volumes were calculated by the formula: volume ¼
(length þ [width]2)/2).
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Results
In vivo xenografts maintain growth pattern and
transdifferentiation of original tumor
To determine how well PDXs of NSCLCs reﬂected their
original primary tumor sample, matched tumor and sequential
xenograft passages were proﬁled for growth pattern/architec-
ture, and epithelial or mesenchymal phenotype. Of 36 suc-
cessfully engrafted NSCLC tumors, 94% of the corresponding
original patient tumor displayed a destructive (angiogenic)
growth pattern (29, 30), with destruction of the normal lung
parenchyma and inﬁltration with tumor-associated stroma
(Fig. 1). This destructive pattern was maintained in all
observed subsequent passages with murine stroma replacing
the human counterpart over passage. The remaining two
tumors displayed an alveolar growth pattern (nonangiogenic)
with the tumor cell nest ﬁlling the alveolar spaces and areas of
necrosis forming in central areas. In the corresponding xeno-
grafts, the gross morphology appeared to be maintained even
in the absence of the alveolar septa. Tumor cell nests with
small necrotic cores were organized by a surrounding web of
stroma (Fig. 1). To determine whether there was phenotypic
drift, epithelial and mesenchymal markers (E-cadherin and
vimentin respectively) were quantiﬁed in 29 lines. Evidence
of epithelial-to-mesenchymal transition (EMT) (absence of
E-Cadherin or expression of vimentin in tumor cells) was seen
in 38% (11/29) of patient tumors. Initial phenotype of
tumor cells (epithelial or mesenchymal) was maintained in
79% (23/29) of cell lines, with one tumor showing some
evidence of mesenchymal to epithelial transition (MET) and
ﬁve showing signs of EMT (Fig. 1).
3D-TGA is a suitable microenvironment for PDXs from
different tumor types and can be used to determine
chemosensitivity in the presence and absence of stroma
Given the established PDX lines preserved the characteristics of
the original patient tumor, we developed an ex vivo assay, utilizing
tumor cells from the xenograftmaterial, as both a surrogatemodel
of the original tumor and a higher throughput alternative to PDX
xenograft drug efﬁcacy testing. To maximize the relevance of the
TME-relevant ex vivo assay we adapted the 3D-TGA originally
described by Sasser and colleagues (26) incorporating patient-
derived tumor and stromal cells. Disaggregated xenografted
tumors were cultured in the presence or absence of CAFs or MSCs
(3:1 tumor: stroma ratio) in basement membrane extract. Tumor
cells from NSCLCs (n ¼ 11) were successfully grown in the 3D-
TGA over a 7-day assay (Fig. 2 and Supplementary Figs. S2 and
S3). Growth of tumor cells in 5 of 10 cases was enhanced in the
presence of CAFs, including 1 example entirely dependent upon
stromal support (LU42; see Supplementary Fig. S3). To monitor
growth of stromal cells in cocultures independently of the tumor
cells, CAFs constitutively expressing tdTomato were generated
and growth monitored using tdTomato ﬂuorescence. As expected
in low stiffness matrix, stromal cells either alone or in coculture
remained static or grew minimally through the assay, whereas
tumor cells grew progressively (Supplementary Fig. S3).
Through the inclusion of serial dilutions of drug in the liquid
overlay, the 3D-TGA was amenable for pharmacologic endpoint
assay (Fig. 2). The applicability of this assay was further demon-
strated in colorectal (n ¼ 9), esophageal (n ¼ 1), and pancreatic
tumors (n¼ 2) and in colorectal lungmetastases (n¼ 5; examples
in Fig. 2A; growth curves in Supplementary Fig. S4), indicating
that the 3D-TGA may be suitable for many solid tumor types.
Figure 1.
NSCLC PDX lines maintain architecture and EMT phenotype of original patient tumor. FFPE samples from matched patient and PDX samples were sectioned
and stained with H&E to reveal architecture and by IHC for E-cadherin and vimentin for EMT phenotype. A, patient LU132 and P1 xenograft show destructive
architecture. B, patient LU7 and P0 xenograft show an alveolar growth pattern. C and E, patient LU56 and P1 xenograft show epithelial phenotype. D and F, patient
LU78 and P1 xenograft show mesenchymal phenotype.
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We observed low sensitivity to single standard-of-care (SOC)
agents (carboplatin, cisplatin, gemcitabine, and paclitaxel) in
NSCLC samples. Therewere some large changes in drug sensitivity
to SOC agent in the presence of stromal cells (examples shown
in Fig. 2C and D). LU60 (ADC) and LU99 (LCNEC) showed a
modest increase in resistance (<10-fold) in the presence ofCAFs in
response to cisplatin, carboplatin or paclitaxel, but 9,500-fold
(LU60) and 930-fold (LU99) decreases in sensitivity to gemcita-
bine when CAFs were present. This is an example that demon-
stratesmodels used indrugdevelopment that lackCAF interaction
may fail to identify ineffective drugs.
A single patient (LU102) was found to harbor a pointmutation
in exon 21 of the tyrosine kinase domain (L858R) of EGFR, which
results in oncogene-addiction and exquisite sensitivity to EGFR-
TKIs such as erlotinib and geﬁtinib. In the 3D-TGA assay, LU102
showed nanomolar sensitivity to erlotinib and geﬁtinib. The
presence of either CAFs or MSCs reduced the sensitivity in the
EGF-R–mutant patientwhen treatedwith erlotinib (CAFs 7.7-fold,
MSCs 27-fold) and geﬁtinib (CAFs 11.2-fold, MSCs 39-fold; Fig.
2E). TheCAFsandMSCsusedareknown tohavehigh levelsofHGF
expression (Supplementary Fig. S5), which has been implicated in
acquired stromal-induced resistance to EGF-R inhibitors (31, 32).
Figure 2.
PDX tumor cell growth and drug sensitivity with supportive stroma in the 3D-TGA. A, representative growth of PDX-derived tumor cells in the 3D-TGA. Tumors
were enzymatically disaggregated and single-cell suspensions entered into 3D-TGA with tumor cells only (red line) or in the presence of stromal cells
(green line) at a ratio of 3 epithelial to 1 stromal cell. Growth was monitored by AlamarBlue ﬂuorescent viability assay in triplicate wells; error bars, one standard
deviation. B, drug sensitivity to SOC chemotherapeutics; drugs were overlaid on day 3 of assay and ﬁnal day sensitivity assayed as a percentage of media-
only control on day 7 by the AlamarBlue assay. Horizontal dotted lines, IC50; vertical dashed line, peak serum concentration of drug achieved in humans at typical
doses; see Supplementary Table S1. C and D, examples of IC50 curves produced from PDX-derived tumor lines grown in the 3D-TGA, where the presence of patient-
derived CAFs increased resistance to therapy. E, example of EGFR-mutant sensitivity to EGFR inhibitors and resistance induced by CAFs or MSCs. (m)CRC,
(metastatic) colorectal carcinoma; AdC, adenocarcinoma; LCNEC, large-cell neuroendocrine carcinoma.
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3D-TGA modeling in early-stage NSCLC reveals broad levels of
de novo drug resistance potentiated by the presence of stroma
To further investigate the sensitivity of PDX samples, 30 che-
mona€ve NSCLC patients were screened with a broad panel of
single and combination SOC agents in the presence and absence
of stromal support (Fig. 3A). To classify the relevance of individ-
ual drug-sensitivity results, IC50 values were compared with
maximum reported serum concentrations achievable in humans
at typical human doses (Supplementary Table S1). Until the
advent of targeted agents, the mainstay of chemotherapy for
higher stage NSCLC has been platinum-based combinations. For
both platinum agents (carboplatin and cisplatin) and other
cytotoxic agents tested (docetaxel, gemcitabine, paclitaxel, peme-
trexed, and vinorelbine), 50% or more patients were resistant
when drugs were tested as single agents in the absence of stromal
support and70%or greater in the presence of stroma. For all drugs
tested, the presence of stroma increased the number of patients
showing drug resistance. Responses to combination of carbopla-
tin/paclitaxel followed a similar pattern to those when tested as
single agents, with low efﬁcacy and increased resistance in the
presence of stroma. In the absence of stroma, samples tested with
combinations of cisplatin and either gemcitabine or vinorelbine
showed the lowest levels of resistance (40% and 38%, respective-
ly). The presence of stroma increased the number of samples
classed as resistant for the gemcitabine/cisplatin combination;
however, the combination of vinorelbine with cisplatin was
almost unaffected by the presence of stroma. The vinorelbine/
cisplatin combination was by far the most efﬁcacious modality
tested in the presence of stroma, with 50% of patients showing
drug sensitivity. Figure 3B shows individual patient IC50 values for
cisplatin, vinorelbine, and their combination (data for all drugs in
Supplementary Fig. S6), where it can be seen that the presence of
patient-derived CAFs causes a statistically signiﬁcant decrease in
sensitivity to both single agents while no difference was observed
when tested in combination.
Overall, the data for cytotoxic reagents reﬂects the very poor
response rates to standard chemotherapies seen in the clinicwhere
they are predominately used in higher stage patients and indicates
an intrinsic disease-speciﬁc resistance to these therapies rather
than one associated with late-stage disease or acquired resistance.
The presence of CAFs caused a modest overall increase in resis-
tance to SOC; however, therewere noticeable individual examples
where the presence of CAFs profoundly altered drug sensitivity
(Fig. 2).
EGFR tyrosine kinase (TK)–targeted agents erlotinib and geﬁ-
tinibwere tested as single agents and only 1 of 30 patients showed
response. Indeed, this was the only patient (LU102 discussed
above) shown to have amutated EGFR and displayed nanomolar
sensitivity, >1,000-fold more sensitive than patients with the
rest of the cohort (mean IC50 for erlotinib treatment of
EGFRWT¼ 34 mmol/L and LU102 EGFRmt¼ 0.03 nmol/L; Fig. 2).
HDAC inhibitors JNJ-26481585 and panobinostat efﬁciently
kill multidrug-resistant NSCLC specimens
There is a clinical need for antineoplastic agents with greater
efﬁcacy in the NSCLC setting and given the cohort of patients
studied here showed a high degree of de novo resistance to SOC
agents, novel therapies were considered. HDAC inhibitors induce
apoptosis, cell-cycle arrest, and terminal differentiation in a
variety of human tumors and, while currently only clinically
licensed for hematological malignancies, show promise in solid
tumors, including NSCLC (33). Three class I HDAC inhibitors—
JNJ-26481585 (34, 35), panobinostat, and vorinostat—were test-
ed in the panel of patient-derived NSCLC specimens. Samples
were classiﬁed as sensitive, if the IC50 was below the achievable
serum concentrations in humans (1.5 mmol/L panobinostat, 1.81
mmol/L vorinostat: see Supplementary Table S1); as this infor-
mation was unavailable for JNJ-26481585, 1 mmol/L was arbi-
trarily set as the cutoff. Patient samples showed a high level of
sensitivity to both JNJ-26481585 (83%, 24/29) and panobinostat
(80%, 16/20)with nanomolar IC50s (Fig. 4).While the number of
those classiﬁed as sensitive was the same in the presence or
absence of patient-derived CAFs, for both JNJ-26481585 and
panobinostat there was a signiﬁcant increase in IC50 values in
samples tested in the presence of CAFs (Supplementary Fig. S7).
Vorinostat was less efﬁcacious, with only 33% (7/21) and 5%
(1/21) of patient samples showing sensitivity in the absence or
presence of CAFs, respectively. The clinical toxicity of high-dose
HDAC inhibitors may limit their use as single agents; however,
there is the potential that global epigenetic changes can resensitize
resistant tumors to SOC agents. JNJ-26481585 was tested in
combination with SOC agents cisplatin, gemcitabine, vinorel-
bine, or pemetrexed (adenocarcinomas only). As the majority of
samples were sensitive to the JNJ-26481585 single agent, high
sensitivities were seen to the combinations. Positive interactions
between JNJ-26481585 and SOC agents (additive or synergistic)
were seen for 57% of samples tested. Of note, two samples (LU91
and LU108), which showed low sensitivity to SOCs and JNJ-
26481585 as single agents, had favorable interactionwith all three
SOCs tested (vinorelbine, cisplatin, and gemcitabine). However,
in the case of LU91 and LU108 this increased sensitivity was not
sufﬁcient to bring IC50 values into clinical relevant range (Fig. 4).
There was one example of dramatic synergy between JNJ-
26481585 and gemcitabine in patient LU126 where the addition
of 5 nmol/L JNJ-26481585 to gemcitabine reduced the IC50 by
over 1,000-fold (Fig. 4B–D).
3D-TGA recapitulates in vivo PDX SOC sensitivities
Sensitivity to SOC agents was determined in PDX in vivo
models, and data were compared with that generated from 3D-
TGA line at early passage. PDX lines from 10 patients were
passaged into MF-1 nude mice and treated with paclitaxel/carbo-
platin combination or pemetrexed. Reponses were determined by
measurement of mean tumor volume in comparison with vehicle
control. The majority of PDX lines showed de novo resistance to
SOC agents, with 10 of 10 showing no response to pemetrexed
and only 3 of 10 showing response to carboplatin/paclitaxel
combination. As shown in Fig. 5 these correlated with data from
3D-TGA in which all lines were resistant to pemetrexed whereas
LU11, LU57, and LU78 showed some sensitivity to paclitaxel/
carboplatin. Interestingly in the 3D-TGA it was clear that LU78
was sensitive to carboplatin as a single agent, whereas LU11 and
LU57 only showed sensitivity to the combination. Additionally,
LU102 demonstrated sensitivity to erlotinib in vivo (as it did in
3D-TGA), where a dramatic sensitivity was observed, with reduc-
tion and elimination of established tumors (Fig. 5D).
Discussion
Here, we describe a novel ex vivo 3D assay which uses close-to-
patient material, derived from PDX models, with matched stro-
mal support to determine drug sensitivity in a cohort of stage I to
3D Tumor Growth Assays with Low-Passage Patient Tumors
www.aacrjournals.org Mol Cancer Ther; 15(4) April 2016 757
Figure 3.
Drug sensitivity of NSCLC patient lines to SOC agents in 3D-TGA. PDX-derived tumor cells (n ¼ 30) were grown in the 3D-TGA in the presence or absence of
patient-derived CAFs and serial drug dilution was applied on day 3 as single agents or combinations at ﬁxed ratio. A, endpoint cell viability was measured at
day 7 by AlamarBlue assay; IC50 curves were generated using GraphPad Prism Software; and samples were classiﬁed as sensitive (green), borderline (amber), and
resistant (red) in comparison with achievable serum concentrations in humans (Supplementary Table S1): sensitive (<90%), borderline (90%–110%), resistant
(>110%). White boxes not done. B, sensitivity of patient cells to cisplatin and vinorelbine but not their combination is reduced in the presence of CAFs. Paired IC50
values for individual patients in the presence and absence of CAFs are shown,withmean and range shownby box andwhiskers. Signiﬁcance of difference is shown as
P value calculated by ratio paired t test. AdC, adenocarcinoma; AdS, adenosquamous; SCC, squamous cell carcinoma; UN, unknown; carbo, carboplatin; pacli,
paclitaxel; gem, gemcitabine; cis, cisplatin; vin, vinorlebine; pem, pemetrexed.
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III NSCLC patients undergoing surgery. Despite most of the
patients being chemotherapy na€ve, the majority showed high
levels of intrinsic resistance to a panel of SOC agents and combi-
nations, with many showing higher levels of resistance when
tested in the presence of CAFs. HDAC inhibitors JNJ-26481585
and panobinostat showed promising results, including when
tested in combination with current SOC agents, underlining their
promise for solid tumor therapy. The 3D-TGA showed broader
applicability across other tumor indications and, in a cohort of 10
patients, correlation between the 3D-TGA and standard in vivo
xenograft sensitivity testing indicated both its relevance and
potential utility in reducing animal testing.
Thepreservationof phenotype andgenotype, displayedbyPDX
models (11), is vital to the development of new antineoplastics,
not least in the age of targeted therapeutics (4, 36). Similar to
Perez-Soler and colleagues (9), tissue architecture was well main-
tained in our NSCLC samples. In addition, using E-cadherin
(epithelial) and vimentin (mesenchymal) asmarkers in this study
it was evident that our patients were heterogeneous for the
presence of EMT, implicated in drug resistance in NSCLC (37)
as well as tumor invasionmetastasis and progression in a range of
tumor types (38), at the time of surgery and that the pattern of E-
cadherin/vimentin staining was maintained in the majority of
PDX lines studied.
Figure 4.
Drug sensitivity of NSCLC patient lines to HDAC inhibitors in 3D-TGA. PDX-derived tumor cells (n ¼ 29) were grown in the 3D-TGA in the presence or absence of
patient-derived CAFs, and serial drug dilution was applied on day 3 as single agents or combinations at ﬁxed ratio. Endpoint cell viability was measured at
day7byAlamarBlue assay, and IC50 curvesweregeneratedusingGraphPadPrismSoftware. A, summary tablewith samples classiﬁed as sensitive (green), borderline
(amber), and resistant (red) in comparison with achievable serum concentrations in humans (1.5 mmol/L panobinostat, 1.81 mmol/L vorinostat) and for
JNJ-26481585 (JNJ585) arbitrarily at 1 mmol/L: sensitive (<90%), borderline (90%–110%), resistant (>110%). White boxes, not done. B–D, example of synergy
seen with LU126. B, JNJ26481585 single agent. C, gemcitabine single agent. D, gemcitabine/JNJ26481585 (10:1 molar ratio; scale gemcitabine). AdC,
adenocarcinoma; AdS, adenosquamous; SCC, squamous cell carcinoma; UN, unknown; carbo, carboplatin; pacli, paclitaxel; gem, gemcitabine; cis, cisplatin; vin,
vinorlebine; pem, pemetrexed; 585, JNJ-26481585.
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The drive towardmore realistic in vitro tumor culture has seen a
great deal of effort focused on the establishment of 3D culture
systems (16, 18). However, 3D models, such as spheroid assays,
can be difﬁcult to adapt to high-throughput applications, lack an
ECM and are also extremely varied in their applicability to
different cell types, especially primary cultures (39). The clono-
genic assay (40) remains the only widely used ex vivo assay of
xenograft or primary tumormaterial; however, such assays are, by
deﬁnition, only able to measure growth and drug sensitivity of a
subset of cells capable of anchorage-independent growth. The
present study aimed to generate not only a close-to-patient
system, but one that was scalable and widely applicable across
different lines and tumor types.
The 3D-TGA model proved to be very adept at growing cells
freshly isolated from xenograft tumors, including cells derived
from a range of solid malignancies (esophageal, pancreatic,
colorectal cancer, and colorectal metastases). Almost all the
cells used survive and proliferate, so subsequent pharmaco-
logical assays measure effects on the entire heterogeneous
population rather than a subset, providing more patient-reﬂec-
tive results. The assay was scalable and easily adapted to 384-
well plate format. From one xenografted tumor 20þ drugs or
combinations could be tested in serial dilution in either the
presence or absence of CAFs/MSCs. The assay makes a step
forward in the alignment to the TME by utilizing a tumor-
derived matrix providing representative biochemical and
Figure 5.
Comparison of in vivo and ex vivo 3D-TGA drug sensitivity of NSCLC patient lines to SOC. PDX-derived tumor cells (n ¼ 10) were grown in MF-1 nude mice
and treated with pemetrexed (100 mg/kg i.p. weekly), carboplatin/paclitaxel combination (50/5 mg/kg i.p. weekly), or erlotinib (25 or 50 mg/kg p.o. q.d.) or
matched vehicle control. Tumor volume was determined by serial caliper measurement; error bars, 1 SD (n > 5 mice). A, comparison of in vivo and 3D-TGA data.
B, example of nonresponse to SOC; LU52. C, example of response to SOC; LU78. D, response to EGFR inhibition in LU102.
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biophysical properties, including acidic pH, physiologic glu-
cose level as well as tissue-aligned stiffness. In order to take this
further, the assay incorporated the most predominant non-
tumor cell type in many solid malignancies: CAFs. Patient-
derived CAFs when screened in 3D coculture broadly increase
proliferation of standard cell lines, and we and others also
observed a similar trend with bone marrow–derived MSCs,
which are one of the putative origins of cancer-associated stem
cells (41). CAFs have been implicated in growth promotion,
EMT, metastasis, and drug resistance, not least in the era of TKIs
(32, 42) and thus their incorporation into the assay seems the
ﬁrst logical step in constructing multicell type ex vivo assays.
To date, PDX lines have been used to screen agents in standard
murine xenograft assays. Due to greater heterogeneity of the tissue
(in comparison with standard cell lines), higher N numbers are
often required, making them expensive, time-consuming, and
requiring the sacriﬁce of more animals. We utilized PDX lines at
low passage, during the normal expansion phase for standard
xenograft testing (4); the low cell number required and short time
scalemeans that amuch greater number of agents, concentrations,
and combinations can be tested at early passage. Where available,
we have correlated the response measured in the 3D-TGA to
subsequent xenograft drug efﬁcacy testing. In many cases, tumors
were nonresponsive to SOC agents in both settings; however,
LU11, LU57, and LU58 showed sensitivity to the combination of
carboplatin and paclitaxel in both 3D and in vivo assays. In
addition, patient LU102, who had an activating EGFR TK muta-
tion, showed hypersensitivity to geﬁtinib and erlotinib in the 3D
assay and excellent response in vivo (Figs. 2 and 5). Clearly the 3D-
TGA does not fully recapitulate the complexity of the TME and
currently cannot be used for some drugs, such as VEGF inhibitors,
which act through angiogenesis not present in the 3D-TGA.
However, for many other classes of drug, this assay has the
potential to limit the need for further downstream xenograft
testing or indeed focus that testing, minimizing both the animals
used and ﬁnancial costs.
It was striking that, in this study, even those in the early stage of
disease had very poor response to SOC agents, suggesting that
current SOC agents are badly suited to treating NSCLC and the
resistance seenwhenused in later-stage diseasemaynot be due per
se to an acquired resistant phenotype (43). Of the single agents
tested, carboplatinwas themost efﬁcaciouswith 43% responding;
however, when tested in the presence of CAFs this fell to 17%.
Indeed, the majority of agents were very poorly effective in the
presence of CAFs both in terms of the number of patients
responding and the mean IC50 values (Fig. 3 and Supplementary
Fig. S6, respectively). Themost efﬁcacious treatment combination
was gemcitabine/cisplatin when tested in the absence of CAFs,
closely followed by vinorelbine/cisplatin. While the gemcitabine/
cisplatin combination was much less efﬁcacious when stromal
cells were present, the combination of vinorelbine and cisplatin
was almost unaffected both in the numbers of patients respond-
ing and mean IC50 values (Fig. 3).
There are a number of examples of ﬁbroblasts inﬂuencing
sensitivity to antineoplastics (44), and it has been seen that their
secretion of awide range of growth factors can lead to resistance to
targeted therapies (32). For example, HGF secretion by ﬁbroblasts
is a key pathway a mediating resistance to EGF-R, RAF, and Her-2
inhibitors (31, 32, 45).Here,weobserved that in the single patient
responsive to erlotinib and geﬁtinib, this sensitivity was dramat-
ically reduced when cocultured with CAFs or MSCs (Fig. 2),
probably due toHGF secretion (bothCAFs andMSCswere shown
to have high HGF expression; data Supplementary Fig. S5).
Resistance to platinum-based chemotherapies has been linked
to expression of drug transporters, such as the ATP-binding
cassette transporter (ABC) family; here, it was clear that stromal
cells also inﬂuence drug sensitivity to platinum agents and their
combinations. While the mechanism has yet to be determined, it
has been recently reported that MSCs stimulate resistance to
carboplatin and cisplatin via secretion of platinum-induced poly-
unsaturated fatty acids (46).
We observed notable individual de-sensitization to gemci-
tabine in the presence of CAFs (Fig. 2), and overall 10 times
fewer patients were sensitive to gemcitabine in the presence of
CAFs (3%) than in their absence (33%). In pancreatic cancer, a
direct role for ﬁbroblasts in gemcitabine resistance via
decreased expression of caspase and its inducer STAT-1 has
been demonstrated; interestingly this could be overcome by
treatment with HDAC inhibitors, relieving the STAT-1 blockade
and recapitulating sensitivity (47). In our study, the majority of
tumors were sensitive to the HDAC inhibitor JNJ-26481585
and so, as expected, the combination with gemcitabine was also
very efﬁcacious, with speciﬁc examples of synergy between the
two drugs (e.g., LU126; Fig. 4).
HDAC inhibitors have shown potent preclinical antitumor
activity, but so far only two agents, vorinostat and romidepsin,
have become FDA licensed with short half-lives and toxicity at
higher doses being limiting factors (48). A phase I clinical trial
showed JNJ-26481585 to have a much greater plasma half-life
of 8.8 hours in patients with advanced solid tumors compared
to other HDAC inhibitors, such as vorinostat and romidepsin
(49, 50), and it shows promise for use in solid tumors either as
a single agent or in combination with SOC (35). The dismal
plight of those with advanced NSCLC and the observation here
that even early-stage tumors are insensitive to current SOCs
highlights the need for novel therapeutic or combinatorial
options in this setting. In the current study, 80% or greater
models showed sensitivity to JNJ-26481585 and panobinostat;
while the presence of CAFs increased IC50s for both agents their
potency meant that IC50s were still in the nanomolar range.
Taken together, the study provides evidence from novel, close-
to-patient models that JNJ-26481585 may be of utility in the
treatment of NSCLC either as a single agent or as combination
therapy.
In the preclinical arena, the 3D-TGA has the potential to
accelerate research utilizing PDX models by providing a rapid
and scalable ex vivo drug-sensitivity screen of multiple single
and combinatorial agents. It has also shown its utility for
identifying those treatment modalities susceptible to stromal
resistance. In the future, through patient-speciﬁc proﬁling, it
may be used to direct treatment options and for biomarker
identiﬁcation of patient responder/nonresponder. The utility of
3D-TGAs for personalized medicine may be strengthened if the
xenografting stage could be bypassed via direct embedding of
disaggregated patient tumor cells into the assay, eliminating
animal usage, and reducing cost and in vitro manipulation. A
direct TME-aligned ex vivo 3D culture system is the subject of
our future research.
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